title: [Study of visual field and vigabatrin treatment in children].
abstract: BACKGROUND
  Concentric visual field defects have been described in association with vigabatrin, a GABA mimetic antiepileptic agent. Few cases have been reported in children.
  
  
  METHODS
  A systematic ophthalmological examination was performed in 14 children treated with vigabatrin for seizures. A manual kinetic perimetry test (Goldmann) was done in 11 cases. The ERG was recorded in the 3 cases where perimetry could not be done.
  
  
  RESULTS
  All children were asymptomatic. The mean age was 9.6 years. The mean duration of vigabatrin treatment was 41 months. The visual field was abnormal when central and peripheral fields were constricted. A visual field defect was discovered in 6 cases: 4 were severe, 2 were mild. When vigabatrin treatment was stopped, 1 case became worse, 1 case was slightly better, and 1 case remained stationary. A disturbed ERG was found in 3 children (depressed b-wave, raised a/b ratio).
  
  
  CONCLUSIONS
  The visual field defects discovered in children treated with vigabatrin are similar to those described in adults. The incidence and progression of visual field constriction in children with and after vigabatrin treatment are not yet well known. Children treated with vigabatrin should therefore have systematic and regular ophthalmological perimetry, and ERG examinations.
authors.affiliation: Service d'Ophtalmologie, Hôpital d'Enfants Armand Trousseau.
authors.forename: B
authors.initials: B
authors.lastname: Pelosse
authors.forename: M
authors.initials: M
authors.lastname: Momtchilova
authors.forename: A
authors.initials: A
authors.lastname: Roubergue
authors.forename: D
authors.initials: D
authors.lastname: Doummar
authors.forename: T
authors.initials: T
authors.lastname: Billette de Villemeur
authors.forename: L
authors.initials: L
authors.lastname: Laroche
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D020888:Vigabatrin / Q000009:adverse effects*; D014794:Visual Fields / Q000187:drug effects*
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin